These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8863101)

  • 1. The concept of cardioreparation: Part 2. Medical implications of cardioreparation.
    Cleland JG; Dewhurst NG; Murphy RL; Struijker Boudier HA; Tan LB; Visser CA
    J Cardiovasc Risk; 1996 Jun; 3(3):287-93. PubMed ID: 8863101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The concept of cardioreparation: Part 1. Pathophysiology of remodelling.
    Brilla CG; Murphy RL; Smits JF; Struijker Boudier HA; Tan LB
    J Cardiovasc Risk; 1996 Jun; 3(3):281-5. PubMed ID: 8863100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD; Udelson JE; Konstam MA
    Curr Opin Cardiol; 1998 May; 13(3):162-7. PubMed ID: 9649938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials.
    Moser M; Hebert PR
    J Am Coll Cardiol; 1996 Apr; 27(5):1214-8. PubMed ID: 8609345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies.
    Brilla CG; Rupp H; Maisch B
    Herz; 2003 Dec; 28(8):744-53. PubMed ID: 14689110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular remodeling and angiotensin-converting enzyme inhibitors.
    Goldstein S; Sabbah H
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S27-31. PubMed ID: 7700061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertensive heart disease.
    Diamond JA; Phillips RA
    Hypertens Res; 2005 Mar; 28(3):191-202. PubMed ID: 16097361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ACE inhibition on neurohormones.
    Remme WJ
    Eur Heart J; 1998 Sep; 19 Suppl J():J16-23. PubMed ID: 9796836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current aspects of ACE inhibitor therapy from the cardiologic viewpoint].
    Klein W; Eber B; Gasser R; Stoschitzky K; Schumacher M; Fruhwald FM; Zweiker R
    Wien Med Wochenschr; 1996; 146(11):221-4. PubMed ID: 8928518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin converting enzyme inhibitors and the cardiovascular system.
    Dzau VJ
    J Hypertens Suppl; 1992 Jun; 10(3):S3-10. PubMed ID: 1386105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.
    Messerli FH; Ketelhut R
    J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S7-13. PubMed ID: 7507540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment by angiotensin converting enzyme inhibitors after myocardial infarction. What did the clinical trials teach us?].
    Guéret P; Garot J; Barnier P
    Arch Mal Coeur Vaiss; 1996 Aug; 89 Spec No 3():33-8. PubMed ID: 8949316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
    Banerjee A; Talreja A; Sonnenblick EH; LeJemtel TH
    Mt Sinai J Med; 2003 Sep; 70(4):225-31. PubMed ID: 12968195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.